Progenics Pharma Stock Analysis, Valuation (NASDAQ:PGNX)

Add to My Stocks
$7.51 $0.11 (1.44%) PGNX stock closing price May 24, 2018 (Closing)
Watch Robo Advisor Video of PGNX Stock Analysis
Progenics Pharma
Updated on : May 24, 2018
previous close
PGNX 7.5 (0%)
S&P 500 2727.8 (0%)
Closing Price On: May 24, 2018
stock rating
RATING: ★★★★★★★★★★ (0/5)
Industry :
Medical-Generic Drugs
Sector :
5 Quarter Revenue
Revenue Growth
Compared to the industry
Long Term Growth
5 Year CAGR:
Operating Profit
Operating Margin:
Sector Average:
5 Quarter Net Profit
Net Margins
LTM Margin
Debt/Equity Ratio
Debt/Equity Ratio:
Compared to the industry
Cash Flow
Operating cash flow:
Net Income:
Recent Growth
Long Term Growth
Operating Margins
Net Margins
High Debt Burden
Rating: ★★★★★★★★★★ (0/5)
Relative Valuation
Industry PS :
Sector:   Medical.   *PE adjusted for one time items.
Other Metrics
Return on Invested Capital:
Return on Equity:
Free Cash Flow Margin:
Double Tap To Exit Full Screen

Progenics Pharma Stock Analysis

101 5 2

Take a look at Amigobulls Progenics Pharma stock analysis video. This video puts forward our latest analysis highlighting the pros and cons for PGNX stock.

Note: Amigobulls stock rating is our opinion based on the historical performance of the company's fundamentals. It is not indicative of the future performance of the stock.

Progenics Pharmaceuticals, Inc. Stock Rating 2.1/5

Amigobulls PGNX stock analysis takes into account various financial ratios like relative valuation, Progenics Pharma revenue, growth and return on equity based on latest quarter 2018 Q1 financial statements. We also check Progenics Pharma dividend performance. Progenics Pharma valuation analysis is based on relative valuation multiples like PE ratio and price to sales ratio. Progenics Pharma stock rating encapsulates our opinion about the company based on the fundamentals.

Should you buy PGNX stock?

  • Progenics Pharma sales grew by 35.7% year on year in 2018 Q1.

Should you sell PGNX stock?

  • The company saw an average annual sales decline of -2.2% in sales over the last 5 years.
  • Progenics Pharma registered a negative operating margin of -442.8% (average) over the Trailing Twelve Months (TTM).
  • Progenics Pharma registered an average TTM Net loss of -383.1%.
  • With a debt/equity ratio of  0.82, Progenics Pharma is highly leveraged in comparison to Medical peers.
  • The lack of profits renders the PE ratio useless for PGNX stock.
  • The company is trading at a price to sales multiple of 43.4, which is overvalued in comparison to the Medical-Generic Drugs industry average multiple of 6.5.
  • The company has a negative Return on Invested Capital of -129.7%, which is a red flag.
  • A negative ROE of -69.1% indicates that the company is not able to generate profits with the money shareholders have invested.
  • The company has negative Free Cash Flows (FCF), with a negative FCF margin of -447.6%.

Comments on this video and Progenics Pharma stock

Investors can make use of the Amigobulls Progenics Pharma stock analysis to ascertain how PGNX stock fares in fundamental analysis investment criteria. Fundamentals of a company give detailed information which helps in making invesment decisions.

Progenics Pharma revenue growth is an indicator of the demand for a company's products while profit margin is indicative of company's pricing power and pricing strategy. One can also combine technical analysis and fundamental analysis to get a holistic picture about PGNX stock.